Share

Interview of EORTC members about COVID-19 impact on cancer clinical trials

The COVID-19 pandemic has affected cancer clinical trials in many ways, creating challenges and new opportunities.

Recruitment of many studies slowed down, patients did not dare to go to the hospital due to the fear of infection and mobility limitations as shortage of research staff.

During the pandemic, clinical investigators had to adapt quickly to continue the follow-up of their patients by setting remote monitoring, remote dispensation of medications for patients, telematics clinical visits, etc.

Our members share their stories on the impact of the pandemic and how they overcame the challenges, which resulted in being beneficial to patients.

Watch the interviews of our members:

 

Prof. Josep Tabernero, Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain

 

Prof. Yolande Lievens, UZ Ghent, Belgium

 

Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

 

Prof. Kristin Bjordal, University of Oslo, Norway

 

Prof. Jean-Yves Blay, Centre Léon Bérard, Lyon, France

Back to news list

Related News

  • New European AI assistant to make patient experiences actionable for care and health systems

  • First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer

  • EORTC at ESMO 2026: New findings and ongoing studies

  • EORTC research presented at ESMO 2026

  • EORTC Quality of Life Group at ISOQOL 2026

  • Pink October 2026: Advancing breast cancer research, together

  • EORTC presents new results in neuro-oncology at EANO

  • In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group

  • New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults

  • New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors